一个计算动态模型,用于II型抑制剂与阿斯基米尼布的联合治疗
J Roadnight Sheehan1, Astrid S de Wijn1, Ran Friedman2
1Department of Mechanical and Industrial Engineering, Norwegian University of Science and Technology, Trondheim, Norway.
Protein science : a publication of the Protein Society
|July 17, 2025
概括
这项研究探讨了将II型Abl1抑制剂与阿西米尼布结合起来,以克服癌症治疗抵抗力. 新的ERIC组合指标有效地预测了组合治疗的协同作用,而不需要进行广泛的实验.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 耐药性是治疗慢性髓性白血病 (CML) 等癌症的一个主要挑战.
- 针对性治疗和个性化医疗对于控制耐药性至关重要.
- ML作为研究向治疗耐药性的模型.
研究的目的:
- 调查结合II型Abl1抑制剂与阿西米尼布用于癌症治疗的协同作用潜力.
- 开发一种新的计算指标 (ERIC组合) 用于评估患者相关度的药物组合有效性.
- 提出一种结合策略,以应对由于不同的药物结合部位而导致的治疗耐药性.
主要方法:
- 使用计算模型模拟患者相关度的药物相互作用.
- 检查II型Abl1抑制剂和阿西米尼布的同时联合结合.
- 开发和应用IC50 (ERIC) 的有效比率及其扩展,ERIC组合,用于协同评估.
主要成果:
- 类型II Abl1 抑制剂和阿西米尼布同时联合结合显示出高度的协同作用.
- 埃里克组合指标准确地估计了不同度的组合治疗的有效性.
- 拟议的组合策略显示出对抗阻力的潜在稳定性.
结论:
- 与II型Abl1抑制剂和阿西米尼布的联合治疗是一种对抗CML耐药性的有前途的策略.
- 埃里克组合指标提供了一个计算效率高,数据轻的替代方案,可以替代现有的协同效应评估方法,如ZIP值.
- 这种方法有助于设计和比较药物组合,补充药物协同作用的实验研究.
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:26Pharmacokinetic Models: Comparison and Selection Criterion
152
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
152
01:30Combined Effects of Drugs: Antagonism
9.3K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.3K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:53Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
128
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
128